Akari Therapeutics Analyst Ratings
Akari Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/05/2022 | 178.45% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 11/01/2022 | 642.53% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/13/2020 | 828.16% | B. Riley Securities | $7 → $5 | Maintains | Buy |
| 03/29/2018 | 1385.06% | Canaccord Genuity | $15 → $8 | Maintains | Buy |
| 02/08/2018 | 456.9% | B. Riley Securities | → $3 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/05/2022 | 178.45% | HC Wainwright公司 | → $1.5 | 開始承保 | →購買 |
| 11/01/2022 | 642.53% | 聯盟全球合作伙伴 | → $4 | 開始承保 | →購買 |
| 03/13/2020 | 828.16% | B.萊利證券 | $7 → $5 | 維護 | 買 |
| 03/29/2018 | 1385.06% | 卡納科特·格納奇 | $15 → $8 | 維護 | 買 |
| 02/08/2018 | 456.9% | B.萊利證券 | → $3 | 開始承保 | →中性 |
What is the target price for Akari Therapeutics (AKTX)?
Akari治療公司(AKTX)的目標價格是多少？
The latest price target for Akari Therapeutics (NASDAQ: AKTX) was reported by HC Wainwright & Co. on December 5, 2022. The analyst firm set a price target for $1.50 expecting AKTX to rise to within 12 months (a possible 178.45% upside). 2 analyst firms have reported ratings in the last year.
阿卡里治療公司(納斯達克代碼：AKTX)的最新目標價是由HC Wainwright&Co.於2022年12月5日報道的。這家分析公司將目標價定為1.5美元，預計AKTX將在12個月內上漲(可能上漲178.45%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Akari Therapeutics (AKTX)?
Akari治療公司(AKTX)的最新分析師評級是什麼？
The latest analyst rating for Akari Therapeutics (NASDAQ: AKTX) was provided by HC Wainwright & Co., and Akari Therapeutics initiated their buy rating.
阿卡里治療公司(納斯達克代碼：AKTX)的最新分析師評級由HC Wainwright&Co.提供，阿卡里治療公司啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Akari Therapeutics (AKTX)?
Akari治療公司(AKTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akari Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akari Therapeutics was filed on December 5, 2022 so you should expect the next rating to be made available sometime around December 5, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Akari治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Akari治療公司的上一次評級是在2022年12月5日提交的，所以你應該預計下一次評級將在2023年12月5日左右的某個時候提供。
Is the Analyst Rating Akari Therapeutics (AKTX) correct?
分析師對Akari Treeutics(AKTX)的評級正確嗎？
While ratings are subjective and will change, the latest Akari Therapeutics (AKTX) rating was a initiated with a price target of $0.00 to $1.50. The current price Akari Therapeutics (AKTX) is trading at is $0.54, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Akari治療公司(AKTX)評級是以0.00美元至1.50美元的目標價啟動的。Akari治療公司(AKTX)目前的交易價格為0.54美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。